Key Developments For IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. (IDXX.O) (Nasdaq)
IDEXX Laboratories, Inc. Reaffirms FY 2009 Guidance; Issues FY 2010 Guidance In Line With Analysts' Estimates
IDEXX Laboratories, Inc. updated its fiscal 2009 guidance and expects revenue to be approximately $1.02 billion, which represents relatively flat reported revenues compared to fiscal 2008 and organic revenue growth of approximately 4%. This guidance is unchanged from the previous guidance provided in July 2009, as modest additional currency benefits from the weakening of the U.S. Dollar relative to other major currencies since July are offset by a slight reduction in organic revenue growth and and expects diluted earnings per share (EPS) to be in the range of $1.88-$1.92, an increase from its previous guidance of $1.86-$1.90 due principally to the anticipated currency benefits. For fiscal 2010, it expects revenue to be $1.08 to $1.1 billion, which represents revenue growth of 6% to 8% compared to projected revenue for fiscal 2009, revenue growth adjusted to exclude a projected 2% benefit from foreign exchange rate changes is estimated to be in the range of 4% to 6% and diluted EPS of $2.15 to $2.25. According to Reuters Estimates, analysts are expecting the Company to report EPS of $1.90 on revenues of $1.0 billion for fiscal 2009; EPS of $2.18 on revenues of $1.1 billion for fiscal 2010.
IDEXX Laboratories, Inc. Raises FY 2009 Guidance
IDEXX Laboratories, Inc. updated its fiscal 2009 guidance and expects revenue to be approximately $1.02 billion, which represents relatively flat reported revenues compared to fiscal 2008 and organic revenue growth of approximately 5%. This guidance is higher than the previous guidance of approximately $1.0 billion provided in April 2009, driven by currency benefits from the weakening of the U.S. Dollar relative to other major currencies since April. Organic revenue growth of 5% is unchanged from previous guidance and expects diluted earnings per share (EPS) to be in the range of $1.88-$1.92, an increase from its previous guidance of $1.86-$1.90 due principally to the anticipated currency benefits. According to Reuters Estimates, analysts are expecting the Company to report EPS of $1.87 on revenues of $1.0 billion for the same period.
IDEXX Laboratories, Inc. Lowers FY 2009 Revenue Outlook; Raises Low End Of Prior FY 2009 EPS Outlook To A Range Above Analysts' Estimates
IDEXX Laboratories, Inc. lowered its fiscal 2009 revenue outlook and expects revenues to be approximately $1.0 billion. This outlook is down from the previous outlook of $1.02-$1.04 billion provided in January 2009. Diluted earnings per share (EPS) are expected to be between $1.86-$1.90 as compared to previous outlook of $1.84-$1.90. According to Reuters Estimates, analysts were expecting the Company to report revenues of $1.03 billion and EPS of $1.84 for the same period.
IDEXX Laboratories, Inc. Lowers FY 2009 Revenue Outlook; Narrows FY 2009 EPS Outlook To A Range In Line With Analysts' Estimates
IDEXX Laboratories, Inc. lowered its fiscal 2009 revenue outlook and expects revenues to be $1.02-$1.04 billion, down from the previous outlook of $1.05-$1.07 billion. It narrowed fiscal 2009 earnings outlook and expects diluted earnings per share (EPS) to be between $1.84-$1.90 as compared to the previous outlook of $1.82-$1.92. According to Reuters Estimates, analysts were expecting the Company to report revenues of $1.05 billion and EPS of $1.84 for the same period.
IDEXX Laboratories, Inc. Lowers FY 2008 Revenue Outlook; Raises FY 2008 EPS Outlook; Issues FY 2009 Outlook Below Analysts' Estimates
IDEXX Laboratories, Inc. announced that for fiscal 2008, it has lowered revenue outlook to a range of $1.025 billion to $1.03 billion, updated from guidance of $1.06 billion to $1.07 billion, which represents revenue growth of 11% to 12%. The Company has raised diluted EPS outlook to a range of $1.88 to $1.91, which represents EPS growth of 29% to 31%. This guidance reflects the impact of the reinstatement of the federal research and development tax credit, offset by the effects of the strengthening U.S. dollar and lower organic revenue growth in a few of businesses due to economic and other factors. Diluted EPS excludes the anticipated fourth quarter 2008 disposition of pharmaceutical assets described above. Non-GAAP diluted EPS outlook is raised to a range of $1.86 to $1.89, reflecting growth of 18% to 20%. Non-GAAP diluted EPS excludes the impact of discrete income tax benefits in 2008. For fiscal 2009, it expects revenue to be in the range of $1.05 to $1.07 billion, which represents revenue growth of 2% to 4% compared to projected revenue for 2008. Diluted EPS are expected to be in the range of $1.82 to $1.92. According to Reuters Estimates, analysts on an average are expecting the Company to report revenue of $1.064 billion and non-GAAP earnings per share (EPS) of $1.88 for fiscal 2008; revenue of $1.187 billion and EPS of $2.20 for fiscal 2009
